Borraz-Noriega D, Robledo-Pascual JC, Torres-Pérez JA, Flores-Barrientos OI

Language: Spanish
References: 10
Page: 381-387
PDF size: 355.42 Kb.

ABSTRACT

Objective: To assess the sensitivity and predictive values of BAAR Ziehl-Neelsen and GeneXpert (MTB/RIF) for respiratory and non-respiratory samples in the general population and HIV-patients.
Material and Method: A clinical open, not-random, prospective, descriptive and observational study was done from May 2016 to January 2017. Inclusion criteria were: Patients with radiological, clinical and epidemiological data that suggested tuberculosis within the diagnostic evaluation or risk of having it. Simultaneous sputum or extrapulmonary sample was taken for determination of Ziehl-Neelsen, GeneXpert MTB and culture; the crop was used as a gold standard.
Results: There were included 120 patients, 88 (73.3%) men; the justification for performing the test was severe acute disease (n = 76, 63.3%), the risk factor with the highest prevalence was HIV-AIDS (n = 54, 45.5%) The highest percentage was respiratory (n = 75, 62.5%). The total of samples 89 (74.2%) were negative with respect to BAAR in contrast to GeneXpert and culture, which reported positive in 94 (78.3%).
Conclusions: The stable indicators evaluated in the GeneXpert test showed that it is a useful test especially in extralung samples of patients with HIV-AIDS.

REFERENCES

1. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editores. Harrison. Principios de Medicina Interna Vol. 2. 18a ed. México: McGraw‐Hill; 2012.

2. Boehme C, Nabeta P, Hillemann D, Nicol M, Shenai S, Krapp F, et al. Rapid Molecular Detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005-15 DOI: 10.1056/NEJMoa0907847.

3. Hernández-León C, Badial-Hernández F, Ponce-de-León A, Sierra-Madero JG, Martínez-Gamboa A, Crabtree-Ramírez B, et al. Tuberculosis activa en una cohorte de reclusos infectados por VIH en una cárcel de la Ciudad de México: características clínicas y epidemiológicas. Salud Pública Méx 2012;54(6):571-578.

4. Castellanos M, SalazarM, García M, Romero R, Avena A, Ricaño M.Guía para la atención de personas con Tuberculosis Resistente a Fármacos. México 2015. Disponible en: http://www.cenaprece.salud.gob.mx/programas/interior/ micobacteriosis/descargas/pdf/guia_tb_mfr_ok.pdf

5. Kim YW, Kwak N, Seong M-W, Kim EC, Yoo CG, Kim YW, et al. Accuracy of the Xpert® MTB/RIF assay for the diagnosis of extra- pulmonary tuberculosis in South Korea. Int J Tuberc Lung Dis 19(1) 2015:81-86 http://dx.doi.org/10.5588/ ijtld.14.0500

6. Shah S, Auld S, Brust J, Mathema B, Ismail N, Moodley P, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med 2017;376:243-253 DOI: 10.1056/NEJMoa1604544.

7. Omrani AS, Al-Otaibi MF, Al-Ateah SM, Al-Onazi FM, Baig K, El-Khizzi NA, et al. GeneXpert MTB/RIF testing in the management of patients with active tuberculosis; a real life experience from Saudi Arabia. Infect Chemother 2014;46:30-4. doi:10.3947/ic.2014.46.1.30

8. Caminero JA. Tratamiento de la tuberculosis según el diferente patrón de resistencias. Med Clin 2010;134:173-81. DOI: 10.1016/j.medcli.2008.12.024

9. OMS. Guía para el monitoreo y la evaluación de las actividades de colaboración TB/VIH. 2015;2:44.

10. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editores. Harrison. Principios de Medicina Interna. Vol. 2. 18a ed. México: McGraw‐Hill; 2016.